BELEGGINSMAATSCHAPPIJ NOVENTU B.V. – Trademark Portfolio

Entity Type: 03

BELEGGINSMAATSCHAPPIJ NOVENTU B.V. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 17 (Rubber Goods) — 5 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include ARMTEX, JAFRIB, BLINDEX, and JAFLINE. The owner is based in AMSTERDAM.

HERIKERBERGWEG 238

AMSTERDAM 1001 CM , NL

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

JAFRIB
JAFRIB
Registered 2008
JAFLINE
JAFLINE
Registered 2008
ARMTEX
ARMTEX
Registered 1995
BLINDEX
BLINDEX
Registered 1982

Trademark Classifications

BELEGGINSMAATSCHAPPIJ NOVENTU B.V.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

17
Rubber Goods (5 filings)

Unprocessed and semi-processed rubber, gutta-percha, gum, asbestos, mica

Frequently Asked Questions

How many trademarks does BELEGGINSMAATSCHAPPIJ NOVENTU B.V. have?

BELEGGINSMAATSCHAPPIJ NOVENTU B.V. has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.

What trademark classes does BELEGGINSMAATSCHAPPIJ NOVENTU B.V. file in?

BELEGGINSMAATSCHAPPIJ NOVENTU B.V. files trademarks across 1 Nice Classification class. The most active classes are Class 17 (Rubber Goods). Class 17 covers unprocessed and semi-processed rubber, gutta-percha, gum, asbestos, mica.

What are BELEGGINSMAATSCHAPPIJ NOVENTU B.V.'s most well-known trademarks?

BELEGGINSMAATSCHAPPIJ NOVENTU B.V.'s registered trademark portfolio includes well-known marks such as ARMTEX, JAFRIB, BLINDEX, and JAFLINE. These are among 4 currently registered trademarks in the portfolio.

What is BELEGGINSMAATSCHAPPIJ NOVENTU B.V.'s trademark registration success rate?

BELEGGINSMAATSCHAPPIJ NOVENTU B.V. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.